BioNexus Gene Lab Corp [NASDAQ: BGLC] gained 56.00% or 2.38 points to close at $6.63 with a heavy trading volume of 6652783 shares.
It opened the trading session at $4.92, the shares rose to $7.02 and dropped to $4.51, the range by which the price of stock traded the whole day. The daily chart for BGLC points out that the company has recorded 91.62% gains over the past six months.
If we look at the average trading volume of 989.90K shares, BGLC reached to a volume of 6652783 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about BioNexus Gene Lab Corp [BGLC]:
The Price to Book ratio for the last quarter was 1.53, with the Price to Cash per share for the same quarter was set at 2.00.
Trading performance analysis for BGLC stock
BioNexus Gene Lab Corp [BGLC] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.77. With this latest performance, BGLC shares gained by 123.61% in over the last four-week period, additionally plugging by 91.62% over the last 6 months – not to mention a rise of 137.04% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BGLC stock in for the last two-week period is set at 58.87, with the RSI for the last a single of trading hit 1.50, and the three-weeks RSI is set at 1.19 for BioNexus Gene Lab Corp [BGLC]. The present Moving Average for the last 50 days of trading for this stock 3.74, while it was recorded at 4.74 for the last single week of trading, and 3.41 for the last 200 days.
BioNexus Gene Lab Corp [BGLC]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and BioNexus Gene Lab Corp [BGLC] shares currently have an operating margin of -24.74% and a Gross Margin at 12.78%. BioNexus Gene Lab Corp’s Net Margin is presently recorded at -22.86%.
BioNexus Gene Lab Corp (BGLC) Capital Structure & Debt Analysis
According to recent financial data for BioNexus Gene Lab Corp. ( BGLC), the Return on Equity (ROE) stands at -24.75%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -20.52%, reflecting the company’s efficiency in generating profits from its assets. Additionally, BioNexus Gene Lab Corp’s Return on Invested Capital (ROIC) is -26.74%, showcasing its effectiveness in deploying capital for earnings.
BioNexus Gene Lab Corp (BGLC) Efficiency & Liquidity Metrics
Based on BioNexus Gene Lab Corp’s (BGLC) latest financial statements, the Debt-to-Equity Ratio is 0.03%, indicating its reliance on debt financing relative to shareholder equity.
BioNexus Gene Lab Corp (BGLC) Efficiency & Liquidity Metrics
From an operational efficiency perspective, BioNexus Gene Lab Corp. (BGLC) effectively leverages its workforce, generating an average of -$70666.67 per employee. The company’s liquidity position is robust, with a Current Ratio of 4.19% and a Quick Ratio of 3.44%, indicating strong ability to cover short-term liabilities.
An analysis of Institutional ownership at BioNexus Gene Lab Corp [BGLC]
There are presently around $0.88%, or 1.80% of BGLC stock, in the hands of institutional investors.
